Introduction {#Sec1}
============

Cancers develop from a small subset of cancer stem cells (CSCs). A CSC, as defined by attendees of an American Association for Cancer Research Workshop on Cancer Stem Cells (Clarke et al. [@CR6]), is "a cell within a tumor that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor". In a simple model, cells of the epidermis are classified into two types of proliferating cells as follows: stem cells with high proliferative potential (self-renewal) and transit amplifying cells (progenitor cells) with a low capacity for self-renewal and a high probability of undergoing terminal differentiation (Jones and Watt [@CR21]). The role of human cancer stem cells (CSCs) is now a topic of cancer prevention, and inhibitors of CSCs are attracting much attention as potential therapeutics (Yoshida and Saya [@CR65]).

We found that repeated applications of the green-tea component 5 mg (−)-epigallocatechin gallate (EGCG) before each treatment with 1 μg okadaic acid, a potent tumor promoter and inhibitor of protein phosphatases 1 and 2A (Fujiki and Suganuma [@CR11]), completely prevents tumor promotion on mouse skin in two-stage carcinogenesis experiments initiated using 7,12-dimethylbenz(a)anthracene (DMBA). In contrast, tumors formed in 73.3% of mice treated with DMBA plus okadaic acid at week 20 (Yoshizawa et al. [@CR66]; Fujiki and Okuda [@CR10]).

Breast cancer patients who consume \>5 cups of green tea per day (average eight cups) experience lower recurrence rated compared with patients who consume \<4 cups daily (average three cups) (Nakachi et al. [@CR29]). Further, drinking 10 Japanese-size cups (120 ml/cup) of green tea per day delays cancer onset by 7.3 years in female patients and significantly prevents cancers of the lungs, colorectum, liver, and stomach in patients residing in Saitama Prefecture, Japan (Imai et al. [@CR18]; Nakachi et al. [@CR30]). The prevention of the development of prostate cancer in patients with high-grade prostate intraepithelial neoplasia using capsules of green tea catechins was confirmed in a study conducted in Italy (Bettuzzi et al. [@CR4]). A double-blind randomized clinical phase II prevention trial conducted at Gifu University, Japan revealed that drinking 10 Japanese-size cups of green tea supplemented with green tea tablets prevents the recurrence of 51.6% of colorectal adenomas (Shimizu et al. [@CR42]).

A similar trial conducted at Seoul National University found that laboratory-made tablets of green tea extract and placebo showed 44.2% prevention rate for the recurrence of colorectal adenoma (Shin et al. [@CR43]), because of the reduction of the tumor rate between the groups treated with green tea extract and placebo. Moreover, oral premalignant leukoplakia was prevented in patients at the University of Texas M. D. Anderson Cancer Center who were treated with green tea extract (Tsao et al. [@CR58]). Further, an encouraging development in the field was the design of the first large-scale placebo-controlled trail for the prevention of metachronous adenoma recurrence in the colorectum of patients to be administered green tea extract for 3 years at the University Ulm, Germany (Stingl et al. [@CR45]). The potential significant preventative effects of EGCG are extended to an innovative treatment. Thus, the combination of EGCG or green tea extract and anticancer compounds such as retinoids, nonsteroidal anti-inflammatory drugs (NSAID), paclitaxel, and doxorubicin synergistically enhances the anticancer activity in human cancer cell lines and in mouse xenograft models (Suganuma et al. [@CR48], [@CR49]; Fujiki et al. [@CR14]; Stearns and Wang [@CR555]).

^3^H-EGCG binds to the cell surface membrane and is incorporated into the cytosol and nucleus (Okabe et al. [@CR34]). One to three EGCG molecules bind to single-stranded 18-mers of DNA and RNA (Kuzuhara et al. [@CR23]). Moreover, EGCG inhibits the formation of primary and secondary spheroids and the expression of the pluripotency-maintaining factor genes *Nanog*, *c*-*Myc*, and *Oct4* in human prostate and pancreatic CSCs (Tang et al. [@CR53], [@CR54]). A genetic labeling strategy revealed CSCs during the unperturbed growth of solid tumors on mouse skin (Driessens et al. [@CR8]). These results encouraged us to study whether self-renewal of human CSCs can be prevented using EGCG and whether the combination of EGCG and anticancer drugs reduces the stemness of human CSCs.

We conducted a PubMed search that identified papers reporting the anticancer activity of EGCG against 20 different kinds of human CSCs. For example, the self-renewal of cancer stem-like cells enriched using a spheroid formation assay was investigated (Sugihara and Saya [@CR51]). Numerous investigators identified proteins expressed by CSCs and used them as markers to investigate the inhibitory effects of EGCG on stemness (self-renewal and differentiation). Since similar effects of EGCG on CSCs of various human cancer cell lines have been confirmed, this review of the literature will be useful for the readers to check all collected results, as the whole, and to demonstrate that EGCG inhibits the essential mechanisms that maintain CSCs, because EGCG reduces the expression of stemness markers.

This review discusses the important topics as follows: (1) Human CSCs in four different cancer tissues differentially express stemness markers compared with their respective parental cells. (2) EGCG inhibits the expression by human CSCs of stemness markers such as transcription factors and other proteins that contribute to generating epithelial-mesenchymal transition (EMT) phenotypes, indicating that EGCG generally inhibits the self-renewal of CSCs in cancer tissues. (3) EGCG inhibits the expression of EMT phenotypes by CSCs. (4) The inhibitory effects of EGCG on the stemness of CSCs are weaker compared with those on parental cells. (5) The weak inhibitory effects on the proliferation and differentiation of CSCs by EGCG are synergistically increased using EGCG combined with anticancer drugs. Thus, the combination inhibits the viability of human CSCs.

Human CSCs differentially express stemness markers compared with their parental cells {#Sec2}
=====================================================================================

Human CSCs enriched from primary and secondary spheroids are capable of self-renewal. It is important to study the quantitative differences between the levels of stemness markers between CSCs and parental cells, because CSCs redifferentiate into parental cells when cultured in parental growth conditions, and parental cell lines do not form tumorspheres (Dalla Pozza et al. [@CR7]).

This section reviews studies of six human CSCs and their respective parental cells, which were derived from colorectal cancer (CRC), nasopharyngeal cancer, neuroblastoma, and glioblastoma (Table [1](#Tab1){ref-type="table"}). The human CRC, spheroid-derived CSCs, designated HCT116-SDCSCs, express significantly higher levels of stem cell markers (approximately 4.5-fold and 3.2-fold for *Oct4* and *Nanog*, respectively, compared with the parental cells) (Toden et al. [@CR57]). Oct, Nanog, and Sox2 are transcription factors required for the maintenance of pluripotency by coordinated networks of transcription factors (Kashyap et al. [@CR22]; Sarkar and Hochedlinger [@CR41]; Boumahdi et al. [@CR5]). Moreover, the expression levels of the surface marker CD44 and self-renewal markers Notch, Bmi-1, CD133, and ALDH1 are higher in HCT116-SDCSCs compared with parental cells (Table [1](#Tab1){ref-type="table"}). Aldehyde dehydrogenase (ALDH) is a detoxifying enzyme that catalyzes the oxidation of retinal to retinoic acid (Duester [@CR9]) and is used to isolate stem-like breast cancer cells, which are characterized by their enhanced tumorigenicity and ability to self-renew (Ginestier et al. [@CR15]). The results indicate that HCT116-SDCSCs comprise a higher CSC population compared with that of the parental cell population (Toden et al. [@CR57]).Table 1Human CSCs differentially express stemness markersCancers and names of CSCsMarkers of increased expressionMarkers of decreased expressionReferencesColorectal cancer HCT116-SDCSCsmRNAs: *Oct4*, *Nanog*,Toden et al. ([@CR57])Proteins: CD44, Notch, Bmi-1, CD133, ALDH1Nasopharyngeal cancer TW01 spheremRNAs: *Sox2, Oct4, KLf*-*4*, *Twist, Snail, vimentin, N*-*cadherinE*-*cadherin*Lin et al. ([@CR26]) CNE2- & C666-1-SCsmRNAs: *CD44, Bmi*-*1*, *N*-*cadherin, vimentin*, *TwistE*-*cadherin*Li et al. ([@CR25])Proteins: CD44Neuroblastoma BE(2)-C spheremRNAs: *Nanog, Oct4,ATP7A, DKK2*Nishimura et al. ([@CR31])Glioblastoma U87 GSLCsmRNAs: *ALDH1, CD133,GFAP*Zhang et al. ([@CR70])Proteins: CD133, ALDH1,Cyclin D1

Human nasopharyngeal sphere-derived cells CSCs, designated TW01, express relatively high levels of the stem cell markers Sox2, Oct4, and KLf-4, plus EMT markers including Twist, Snail, and vimentin, along with N-cadherin, compared with parental cells. The relative increases of mRNA levels decreases in the order *vimentin*, *Snail*, *Oct*4, *Sox2*, *Twist*, *KLf*-*4,* and *N*-*cadherin* (Table [1](#Tab1){ref-type="table"}). However, decreased expression of *E*-*cadherin* by TW01 sphere-derived cells was detected (Lin et al. [@CR26]). The results indicate that TW01 sphere-derived cells express EMT phenotypes and self-renewal activity associated with invasive and migratory properties more strongly compared with those of parental cells. Similarly, the human nasopharyngeal spheroid cell lines CNE2-SCs and C666-1-SCs express increased levels of the mRNAs of the stemness markers *CD44* and *Bim*-*1*, the mesenchymal markers *N*-*cadherin* and *vimentin*, and the transcription factor *Twist* compared with those of their respective parental cells (Table [1](#Tab1){ref-type="table"}). Further, decreased levels of the epithelial marker *E*-*cadherin* are expressed by CNE2-SCs and C666-1-SCs. The expression of the CSC marker CD44 by CNE2-SCs and C666-1-SCs is significantly increased compared with that of their respective parental cells (Li et al. [@CR25]). CD44 is an adhesion molecule that binds to osteopontin and hyaluronic acid (Goodison et al. [@CR16]), and CD44^+^ cells in a tumor express high levels of nuclear Bim-1, which identifies CSCs (Prince et al. [@CR40]). These results show that CNE2-SCs and C666-1-SCs have a stronger ability to self-renew and migrate compared with their respective parental cells, suggesting that the tumor spheroid cells are enriched with malignant phenotypes (Li et al. [@CR25]).

Human neuroblastoma BE(2)-C spheres express increased levels of *Nanog* and *Oct4* (approximately 50-fold and 5.0-fold, respectively) compared with the parental cells (Nishimura et al. [@CR31]), consistent with findings for human HCT116-SDCSCs (Toden et al. [@CR57]). The expression levels of markers of neuronal differentiation, Cu^2+^-transporting ATPase alpha polypeptide (*ATP7A*) and dickkopf homolog 2 (*DKK2*), are slightly decreased in BE(2)-C spheres (Table [1](#Tab1){ref-type="table"}). These results indicate that BE(2)-C spheres are enriched in tumor-initiating cells as well as CSCs that are responsible for resistance to chemotherapy and tumor recurrence (Nishimura et al. [@CR31]).

Human glioma stem-like cells designated U87 GSLCs express increased levels of the mRNAs and proteins of the stem cell markers *ALDH1* and *CD133*, decreased levels of the astrocyte differentiation marker glial fibrillary acidic protein (*GFAP*) (Pang et al. [@CR37]) and cell cycle protein cyclin D1, compared with the parental cells U87 (Table [1](#Tab1){ref-type="table"}) (Zhang et al. [@CR70]). ALDH1 is a marker of normal and malignant human mammary stem cells (Ginestier et al. [@CR15]), and GFAP is an intermediate filament protein that is expressed by numerous cell types of the central nervous system, but may represent an autoantigen candidate for type 1 diabetes mellitus (Pang et al. [@CR37]). These results indicate that U87 GSLCs comprise neural stem cells with drug-resistant properties (Zhang et al. [@CR70]).

EGCG inhibits the expression of mRNAs and proteins that serve as stemness markers of human CSCs {#Sec3}
===============================================================================================

EGCG and green tea extract inhibit the growth of human cancer cell lines in culture and in rodents (Suganuma et al. [@CR46]; Fujiki et al. [@CR12], [@CR13]). Therefore, we next studied whether EGCG possesses anticancer activity against drug-resistant human CSCs. The results of studies on 20 human CSCs collected from nine different cancer tissues reveal that EGCG inhibits the expression of mRNAs and proteins that serve as stemness markers, such as *Oct4* and *Nanog*, whereas the expression of a few markers such as Bax and caspase 8 is increased, indicating that EGCG exerts inhibitory effects on human CSCs (Table [2](#Tab2){ref-type="table"}).Table 2EGCG decreases or increases the expression of stemness marker mRNAs and proteins by human CSCsCancers and names of CSCsInhibited expression of stemness markers (mRNAs and proteins)ReferencesBreast CSCs SUM-149 & SUM-190mRNAs: *CCND1, RHOC, BCL*-*XL*Mineva et al. ([@CR27]) SUM-149mRNAs: *FN1, CDHI, vimentin* MDA-MB-231 & MDA-MB-436Proteins: ER-α36, EGFR, p-ERK1/2, p-AKTPan et al. ([@CR36])Lung CSCs A549 & H1299mRNAs: *CD133, CD44, ALDH1A1, Nanog, Oct4*Zhu et al. ([@CR71])Proteins: CD133, CD44, ALDH1A1, Nanog, Oct4, PCNA, cyclin D1, Bcl2, p-GSK3β, β-catenin, c-MycIncreased Bax, caspase 8, cleaved caspase-3 and -9Prostate CSCs PC-3 & LNCaPProteins: XIAP, Bcl2, survivin, vimentin, Slug, Snail, β-cateninTang et al. ([@CR53])Colorectal CSCs HCT116-5FUR & SW480-5FURmRNAs: *Oct4, Nanog*Toden et al. ([@CR57])Proteins: Notch 1, cleaved-Notch 1, c-Myc, Bmi-1, Suz12, Ezh2 HCT116-SDCSCsmRNAs: *CD133, Nanog, ABCC1, ABCG2*Wubetu et al. ([@CR63])Proteins: Nek2, p-AktLiver CSCs HepG2-SDCSCsmRNAs: *CD133, Nanog, ABCC1, ABCG2,*Wubetu et al. ([@CR63])Proteins: Nek2, p-AktPancreatic CSCs Pancreatic CSCsmRNAs: *Nanog, c*-*Myc, Oct4*, *Bcl2, survivin, XIAP*, *SMO, PTCH1, PTCH2, Gli1, Gli2*, *Snail, ZEB1, Slug*Tang et al. ([@CR54]) MIA-PaCa2 & BxPc-3mRNA: *K*-*ras* (by green tea extract)Appari et al. ([@CR3])Head and neck CSCs HNSC (K3, K4, K5)mRNAs: *Oct4, Sox2, Nanog, Notch1, Hey1, Hes1 ABCC2, ABCG2*Lee et al. ([@CR24])Proteins: Oct4, Sox2, Notch1, Hey1, Hes1, ABCC2, ABCG2Increased *involucrin*Nasopharyngeal CSCs TW01 & TW06 spheresmRNAs: *Oct4, KLf*-*4*, *vimentin, Snail*\
Increased *E*-*cadherin*Lin et al. ([@CR26])Glioma CSCs U87 GSLCsmRNAs: *ABCB1, ABCG2, MGMT*Zhang et al. ([@CR70])Proteins: p-Akt, CD133, ALDH1, Bcl2, P-gpIncreased Bax, c-PARP

Breast CSCs: EGCG (40 μg/ml, 87.3 μM) inhibits the expression of genes that promote growth and contribute to the transformed phenotype and survival of SUM-190 spheres. In SUM-149 and SUM-190 cells, EGCG decreases the levels of mRNAs of the proliferation markers cyclin D1 (*CCND1)*; ras homolog family member C (*RHOC*); and B-cell lymphoma-extra large (*BCL*-*XL*), which is a major antiapoptotic protein of the Bcl2 family, as well as decreasing ATP levels. In contrast, the levels of fibronectin 1 (*FN1*), E-cadherin (*CDHI*), and *vimentin* were decreased only in SUM-149 cells (Table [2](#Tab2){ref-type="table"}). These results indicate that tumorsphere formation was inhibited by EGCG (Mineva et al. [@CR27]).

ALDH-positive SUM-149 cells that are functionally active CSCs were implanted into the inguinal mammary fat pad of female non-obese mice with diabetic/severe-combined immunodeficiency. When palpable tumors were detected, mice were administered a 0.1 ml intraperitoneal injection of 16.5 mg/kg EGCG or control PBS five times weekly for 5 weeks. Tumor weight significantly decreases by 28.6 ± 6.5% in EGCG-treated mice (Mineva et al. [@CR27]). The phenotypes of human estrogen receptor (ER)-negative MDA-MB-231 and MDA-MB-436 cells reflect tumors with a poor prognosis. In ER-negative breast cancer cell lines, ER-α36 is overexpressed and is associated with malignant growth (Zhang et al. [@CR69]). EGCG (10--40 μM) inhibits tumorsphere formation and down-regulates ER-α36 expression by 24 h, which is consistent with down-regulation of the epidermal growth factor receptor (EGFR). We found it interesting that the inhibitory effects of EGCG are weak in ER-α36 knockdown cell lines compared with control cells. However, EGCG inhibits the growth of ER-negative human breast CSCs through down-regulation of ER-α36 expression, indicating that EGCG treatment will predict longer survival of patients with mammary cancers (Pan et al. [@CR36]) (Table [2](#Tab2){ref-type="table"}). The longer survival of patients with green tea was reported by Nakachi et al. ([@CR29]), as noted in the Introduction.

Lung CSCs: EGCG (0--100 μM) reduce the mRNA levels of the lung CSC markers *CD133*, *CD44*, *ALDH1A1*, *Nanog,* and *Oct4* in CSC-A549 and CSC-H1299 cells; the protein levels of proliferation markers proliferating cell nuclear antigen (PCNA) and cyclin D1 as well as that of B-cell lymphoma 2 (Bcl2). In contrast, EGCG reduces the protein levels of β-catenin and c-Myc. However, EGCG increases the levels of Bax, caspase 8, and cleaved caspases-3 and -9 (Table [2](#Tab2){ref-type="table"}). These results show that EGCG inhibits proliferation and induces apoptosis of lung CSCs (Zhu et al. [@CR71]). The Wnt/β-catenin pathway is implicated in self-renewal and maintenance of CSCs, and it is dysregulated in human cancers (Jang et al. [@CR19]). EGCG (0--100 μM) inhibited the phosphorylation of glycogen synthase kinase 3β (GSK3β) at Ser 9, which significantly increases the expression of GSK3β, and decreases the expression of β-catenin and its downstream target gene *c*-*Myc*. Thus, EGCG down-regulates the activation of the Wnt/β-catenin pathway in human lung CSCs (Zhu et al. [@CR71]; Oh et al. [@CR32]) (Table [2](#Tab2){ref-type="table"}).

Prostate CSCs: EGCG (0--60 μM) dose-dependently inhibits the growth of tumor spheroids and the self-renewal of prostate CSCs derived from PC-3 and LNCaP cell lines. Nanog is a key regulator of embryonic stem cell self-renewal and pluripotency (Jeter et al. [@CR20]), and the knockdown of Nanog by a short hairpin RNA enhances the antiproliferative effects of EGCG on prostate CSCs (Tang et al. [@CR53]). EGCG (30--60 μM) inhibits the expression of X-linked inhibitor of apoptosis protein (XIAP), Bcl2, and survivin as well as that of the EMT markers vimentin, Slug, Snail, and nuclear β-catenin. These results indicate that EGCG will serve as a useful compound that targets prostate CSCs (Tang et al. [@CR53]) (Table [2](#Tab2){ref-type="table"}).

Colorectal CSCs: 5-Fluorouracil (5FU)-resistant (5FUR) CRC cells exhibit an increased ability to form spheroids compared with parental cells, indicating the presence of a larger CSC population. EGCG (50 μM) inhibits tumorspheroid formation and the expression of the mRNAs of the stem cell markers *Oct4* and *Nanog*. The expression of self-renewal markers that are components of the Notch signaling pathway, Notch1, cleaved-Notch1, and c-Myc as well as that of the polycomb repressive complex subunits Bmi-1, polycomb protein SUZ (Suz12), and enhancer of zeste homologue (Ezh2) is inhibited in 5FUR CRCs treated with EGCG (Toden et al. [@CR57]). EGCG (50 μM) down-regulates the expression of the ATP-binding cassette transporter genes ATP-binding cassette subfamily C member 1 (*ABCC1*) and *ABCG2* and decreases the protein levels of never in mitosis gene related kinase 2 (Nek2), which is involved in mitotic regulation, and phosphorylated Akt, a proto-oncoprotein, in HCT116-SDCSCs (Wubetu et al. [@CR63]).

Liver CSCs: EGCG (50 μM) down-regulates the expression of *CD133, Nanog, ABCC1, and ABCG2* mRNAs as well as that of the Nek2 and p-Akt proteins in human hepatoma HepG2-CSCs to an extent similar to that of HCT116-SDCSCs (Wubetu et al. [@CR63]).

Pancreatic CSCs: Human pancreatic CSCs (CD133^+^/CD44^+^/CD24^+^/epidermal surface antigen ESA^+^) represent the bulk of the pancreatic CSC population. EGCG (0--60 μM) inhibits the growth of tumorspheroids. EGCG inhibits the expression by human pancreatic CSCs of the mRNAs of the pluripotency maintaining transcription factors *Nanog*, *c*-*Myc,* and *Oct4*; the apoptosis-related proteins *Bcl2*, *survivin*, and *X*-*linked inhibitor of apoptosis protein* (*XIAP*); the Sonic hedgehog (Shh) receptors *smoothened* (*SMO*), *Patched*-*1* (*PTCH1*), and *Patched*-*2* (*PTCH2*); the transcription factors *Gli1* and *Gli2*; and the EMT factors *Snail*, *ZEB1*, and *Slug* (Table [2](#Tab2){ref-type="table"}). In contrast, EGCG does not inhibit the expression of *Sox2* (Tang et al. [@CR54]).

Numerous Sox factors act redundantly in the maintenance of stem cells (Sarkar and Hochedlinger [@CR41]). The inhibition of *Nanog* expression by EGCG is important for cancer prevention. The human pancreatic ductal adenocarcinoma (PDA) cell line MIA-PaCa2 has characteristic CSC features. EGCG (40 μM), (−)-epicatechin gallate (ECG, 40 μM), or (−)-catechin gallate (CG, 40 μM) decrease colony-forming activity, and ECG or CG exert stronger effects compared with those of EGCG. Treatment of Mia-PaCa2, BxPc-3, and CSC-enriched PDA cells (PacaDD-183) combined with 40 μM green tea extract enhances the expression of the tumor suppressor microRNA (*miR*-*let*-*7a*), which suppresses the expression of genes encoding stemness markers by binding to the 3′-untranslated region of target mRNAs (Yu et al. [@CR67], [@CR68]). Further, miR-let-7a inhibits the expression of K-ras (Appari et al. [@CR3]). These results indicate that green-tea catechins inhibit colony formation.

Head and neck CSCs: Treatment of three head and neck squamous carcinoma (HNSC) CSCs (K3, K4, and K5) with EGCG (5 and 10 μM) significantly inhibit sphere formation, suggesting that EGCG effectively inhibits the self-renewal of HNSC CSCs. EGCG inhibits the expression of the stem cell markers *Oct4*, *Sox2*, and *Nanog* and increases the expression of the early differentiation marker *involucrin*. EGCG decreases the expression of the mRNAs of the ABC transporters *ABCC2* and *ABCG2* and ABCC2 and ABCG2 proteins, suggesting that suppressing the transcription of *ABCC2* and *ABCG2* transporter genes with EGCG augments cisplatin-mediated chemosensitivity. Further, EGCG inhibits the expression of mRNAs of Notch signaling-pathway target genes *Notch1*, *Hey1*, and *Hes1* and the expression of the proteins Notch1, Hey1, and Hes1 by K3 CSCs (Lee et al. [@CR24]). In contrast, the Notch pathway ligands Delta1, Jag 1, and Jag2 are not affected in cochlear explant culture by EGCG (Gu et al. [@CR17]).

Nasopharyngeal CSCs: EGCG (20--40 μM) inhibits colony formation by TW01 and TW06 sphere-derived cells. EGCG inhibits the expression of the mRNAs of the stemness markers *Oct4* and Krüppel-like factor (*KLf*-*4*) but not that of the mRNAs of *Sox2* and the EMT related proteins vimentin and Snail, but increases that of *E*-*cadherin* in TW01 sphere-derived cells (Lin et al. [@CR26]). KLf-8 plays a key role in oncogenic transformation, induces the EMT, and enhances motility and invasiveness (Wang et al. [@CR60]).

Glioma CSCs: EGCG (0--200 μM) inhibits cell viability, neurosphere formation, and the migration of human glioma stem-like cells (U87 GSLCs). Although EGCG inhibits the expression of the mRNAs of the proteins that confer drug resistance, such as P-glycoprotein (*P*-*gp, ABCB1*), *ABCG2*, and *O*-6-methylguanine-DNA methyltransferase (*MGMT*) in U87 GSLCs, it does not change the protein level of ABCG2. Further, EGCG down-regulates p-Akt as well as the levels of the glioma stem cell markers CD133, ALDH1, Bcl2, and P-gp. In contrast, EGCG increases the levels of Bax and cleaved poly-ADP-ribose polymerase (c-PARP) proteins in U87 GSLCs (Zhang et al. [@CR70]).

EGCG inhibits the expression of EMT phenotypes of CSCs {#Sec4}
======================================================

Tumor progression is frequently associated with up-regulation of vimentin and transcription factors such as Snail, Twist, and Slug as well as down-regulation of E-cadherin (Polyak and Weinberg [@CR39]; Thiery et al. [@CR56]). Functional loss of the cell--cell adhesion molecule E-cadherin is required for the EMT, which induces migration, invasion, and stem cell features (Sobrado et al. [@CR44]). E-cadherin repressors are classified into two groups depending on their effects on the *E*-*cadherin* promoter as follows: Inducers of the EMT and repressors of E-cadherin, such as Snail, zinc finger E-box-binding homeobox (Zeb), E2A immunoglobulin enhancer-binding factor (E47), and KLf-8 that binds to and represses the activity of the *E*-*cadherin* promoter (Peinado et al. [@CR38]; Wang et al. [@CR60]). In contrast, Twist, homeobox protein goosecoid (Goosecoid), basic helix-loop-helix protein (E2.2), and Forkhead box C1 (FoxC1) indirectly repress *E*-*cadherin* transcription (Yang and Weinberg [@CR64]).

We found that EGCG (50 μM) inhibits high expression of vimentin and Slug in H1299 human non-small cell lung cancer cells at a leading edge of a scratch and that EGCG increases the stiffness (Young's modulus) of H1299 and Lu99 cells, suggesting that EGCG inhibits EMT phenotypes through the alterations of membrane organization (Takahashi et al. [@CR52]; Suganuma et al. [@CR50]). The combination of EGCG and cisplatin markedly down-regulate the expression of NF-κB p65, Bmi-1, Twist1, and vimentin and up-regulates E-cadherin in human nasopharyngeal CNE2-SCs from the tumor nodules of nude mice, which is associated with the inhibition of tumorigenesis (Li et al. [@CR25]). We found that EGCG in drinking water inhibits the formation of hematogenous and lymphogenous (spontaneous) metastases by two different B16 melanoma variants in the lungs of C56BL/6 mice (Taniguchi et al. [@CR55]). EGCG induces a twofold increase in the stiffness of highly motile B16-F10 melanoma cells and inhibits their migration (Watanabe et al. [@CR62]).

Inhibitory effects of EGCG on CSCs are weaker than on parental cells {#Sec5}
====================================================================

The acquisition of drug resistance by cancer cells presents a formidable clinical challenge, particularly because drug resistance enables tumor recurrence. When EGCG is administered for cancer prevention, it is necessary to consider the different potencies of EGCG against CSCs and parental cells. Two investigations of nasopharyngeal CSCs and neuroblastoma CSCs found that the effects of EGCG on the inhibition of cell proliferation and the induction of apoptosis differed slightly between sphere-derived and parental cells (Table [3](#Tab3){ref-type="table"}). Specifically, the ID~50~ (dose ″μM″ required to achieve 50% inhibition) of EGCG was calculated from the curves of MTT assays (Fig. [1](#Fig1){ref-type="fig"}a, b). The ID~50~ values of EGCG treatment of TW01 sphere-derived cells and parental cells are approximately 150 and 60 μM, respectively, and approximately 115 μM EGCG and 38 μM EGCG for TW06 sphere-derived and parental cells, respectively (Fig. [1](#Fig1){ref-type="fig"}a, b; Table [3](#Tab3){ref-type="table"}) (Lin et al. [@CR26]). Treatment of BE(2)-C sphere and BE(2)-C parental cells with 50 μM EGCG inhibits cell proliferation by 25.2 and 93.8%, respectively, compared with non-treated cells (Nishimura et al. [@CR31]). Induction of apoptosis using EGCG was determined in sphere-derived and parental TW01 and BE(2)-C cells (Table [3](#Tab3){ref-type="table"}). The results indicate that EGCG is a less effective inhibitor of the sphere-derived cells compared with parental cells, although EGCG inhibits the growth of both.Table 3Inhibitory effects of EGCG on CSCs are weaker than those on parental cells(A) Inhibition of cell proliferation using EGCG**Nasopharyngeal cancer**TW01 sphereTW01 parentalLin et al. ([@CR26])ID~50~ μM15060TW06 sphereTW06 parentalLin et al. ([@CR26])ID~50~ μM11538**Neuroblastoma**BE(2)-C sphereBE(2)-C parentalNishimura et al. ([@CR31])EGCG 50 μM25.2 (% of inhibition)93.8 (%)(B) Induction of apoptosis using EGCG**Nasopharyngeal cancer**TW01 sphereTW01 parentalLin et al. ([@CR26])EGCG 40 μM12.7 (%)63.6 (%)**Neuroblastoma**BE(2)-C sphereBE(2)-C parentalNishimura et al. ([@CR31])EGCG 50 μM9.1 (%)91.7 (%) Fig. 1EGCG inhibits the proliferation of nasopharyngeal CSCs and parental cells. MTT assays of (**a**) TW01 sphere-derived cells (*square*) and TW01 parental cells (*filled square*) and (**b**) TW06 sphere-derived cells (*filled triangle*) and TW06 parental cells (*filled circle*) (Lin et al. [@CR26], Reproduced with the permission of Dr. Yann-Jang Chen)

EGCG combined with anticancer drugs synergistically enhances anticancer activity against human CSCs {#Sec6}
===================================================================================================

We found that the combination of green tea extract and NSAIDs synergistically inhibits tumor development in rodents and induces apoptosis associated with expression of the growth arrest and DNA damage-inducible gene 153 (*GADD153*) and *p21* in the human lung cancer cell line PC-9 (Suganuma et al. [@CR47], [@CR49]). Subsequently, numerous investigators extended these studies by combining EGCG with other green-tea catechins and anticancer drugs in 42 in vitro studies and 13 studies of mouse xenograft models (Fujiki et al. [@CR14]). The combination of EGCG with anticancer drugs frequently induced synergistic anticancer activity against human cancer cell lines.

Considering the evidence indicating that the effects of EGCG on human CSCs are slightly weaker compared with the parental cells, a new strategy is required to increase efficacy. We conducted a literature search that identified studies of five human CSCs treated with the combinations (Table [4](#Tab4){ref-type="table"}). Docetaxel inhibits mitosis, and the combination of EGCG, quercetin, and docetaxel reduces colony formation by two prostate CSC lines compared with controls (Wang et al. [@CR61]) (Table [4](#Tab4){ref-type="table"}). 5FU damages cancer cells during S phase, and cisplatin damages DNA, leading to the induction of apoptosis (Fujiki et al. [@CR14]). The combination of EGCG and 5FU or EGCG and cisplatin reduces the weights of tumors formed by three CSCs derived from the colorectum, head and neck, and nasopharynx (Toden et al. [@CR57]; Lee et al. [@CR24]; Li et al. [@CR25]). The combination of EGCG and anticancer drugs is a promising therapeutic strategy for treating human CSCs.Table 4Combinations of EGCG and anticancer drugs synergistically enhance anticancer activity against human CSCs

Discussion {#Sec7}
==========

It is necessary to briefly discuss the effects of EGCG on normal cells. The antiangiogenic effects of EGCG are not observed in normal endothelial cells (NECs), compared with tumor-associated endothelial cells (TECs) and endothelial progenitor cells (EPCs). The reason why EGCG is inactive on NECs is explained by evidence indicating that the stem cell marker stem cell antigen-1 (*Sca*-*1*) is expressed at a low level in NECs, although it is overexpressed by TECs and EPCs (Ohga et al. [@CR33]). Sca-1 was originally identified as an 18-kDa glycoprotein 1-binding surface protein and is a member of the lymphocyte activation protein-6 family.

The difference between cancer cells and normal cells is a vital subject: Treatment with 87.3 μM EGCG for 48 h resulted in apoptosis in human epidermoid carcinoma cell line (A431), human carcinoma keratinocyte (HaCaT), and human prostate carcinoma cell line (DU145), but 349.1 μM EGCG was not effective on normal human epidermal keratinocytes (NHEK) (Ahmad et al. [@CR1]). EGCG (10--80 μM) for 24 h results in lowering of NF-κB levels in both the cytoplasm and nucleus in a dose-dependent manner in both A431 and NHEK cells. However, EGCG-mediated inhibition of NF-κB constitutive expression and activation, only occurred at a higher dose of EGCG (40--80 μM) in NHEK, compared with A431 cells (Ahmad et al. [@CR2]).

As reported in Introduction, a single topical application of 5 mg was applied to mouse skin. The specific binding of ^3^H-TPA and that of ^3^H-okadaic acid to the receptors in a membrane fraction of normal mouse skin were then determined. Both specific bindings decreased immediately, reaching minimum in 5--10 min. The levels gradually returned to normal, suggesting that EGCG induces the sealing of the membrane on mouse skin because of EGCG-protein interaction (The sealing effects of EGCG), resulting in inhibition of tumor promotion and tumor development associated with internalization of ^3^H-EGCG (Yoshizawa et al. [@CR66]; Okabe et al. [@CR34]).

In contrast to our initial work, recent investigation on the interaction of EGCG and cellular molecules, along with receptor activation and gene expression, have shown outstanding progress in the elucidation of therapeutic mechanisms for green tea catechin: Excessive concentrations of vascular endothelial growth factor (VEGF) increase growth of tumors. VEGF stimulates cellar responses by binding to VEGF receptor-2 (type III receptor tyrosine kinases) on the cell surface, resulting in phosphorylation of VEGFR-2. Treatment of human umbilical vein endothelial cells (HUVECs) with 1 μM EGCG resulted in complete inhibition of VEGF-induced VEGFR-2 activation, indicating that direct interaction of EGCG with VEGF is a significant mechanism. In these circumstances, endothelial nitric oxide synthase is still activated through the PI3K/Akt signaling pathway that is downstream of VEGFR-2 (Moyle et al. [@CR28]). Matrix metalloproteinases (MMPs) are involved in tumor progression, and treatment with 10.9--87.3 μM EGCG inhibited fibroblast conditioned medium (FCM)-induced phosphorylation of ERK1/2 and/or p38 concomitant reduction in MMP-2 and -9 in human prostate carcinoma DU-145 cells. It also inhibited androgen-induced pro-MMP-2 expression in androgen-sensitive human prostate adenocarcinoma LNCaP cells (Vayalil and Katiyar [@CR59]).

Summary {#Sec8}
=======

EGCG and green tea extracts effectively prevent the early stages of cancer, and the combination of EGCG and anticancer drugs is more effective for inhibiting the viability of human CSCs.

ABC

:   ATP-binding cassette

AFM

:   Atomic force microscopy

ALDH

:   Aldehyde dehydrogenase

CSCs

:   Cancer stem cells

CRC

:   Colorectal cancer

DMBA

:   7,12-Dimethylbenz(a)anthracene

EGCG

:   (−)-Epigallocatechin gallate

EGFR

:   Epidermal growth factor receptor

EMT

:   Epithelial-mesenchymal transition

ER

:   Estrogen receptor
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ERK1/2

:   Extracellular-signal regulated kinase 1/2

GP1

:   Glycoprotein 1

Gli1

:   Zinc finger protein GLl1

Hey1

:   Hairy/enhancer-of-split related with YRPW motif protein 1 

K-ras

:   KRAS oncogene

KLf

:   Krüppel-like factor

Myc

:   v-Myc avian myelocytomatosis viral oncogene homolog

Nanog

:   Nanog homeobox protein

Notch1

:   Notch homolog 1

Oct4

:   Octamer-binding transcription factor 4

Patched-1

:   Protein patched homolog 1

SMO

:   A class Frizzled (class F) G protein-coupled receptor

Slug

:   SNAI2

Snail

:   Snail family transcriptional repressor 

Sox2

:   SRY (sex determining region Y)-box 2

Twist

:   Twist family BHLH transcription factor 

Wnt

:   Mammalian homologs of *Drosophila* 'wingless" signaling
